TEM / FQ3 2026 (quarter ended 2026-09-30)

Tempus AI, Inc.

Reported: Nov 2, 2026

Forecast published

Nov 2, 2026 at 3:21 PM PST

Opus 5.5 High in Shortcut

Review incomplete · First posted after earnings

Shortcut

0.04

Normalized diluted EPS

+154.6% vs Street

Off by $0.03 per share

Street

-0.08

Normalized diluted EPS

November 1 consensus snapshot

Off by $0.15 per share

Real

0.07

Reported normalized EPS

Shortcut win

Reported result · Nov 2 ↗ · Provider 0.07 agrees with issuer nonGAAP per-share figure 0.07, distinct from GAAP loss 0.08.

USD per diluted ordinary/common share. Comparisons use unrounded estimates.

Model download

Explore the assumptions and calculations behind the forecast. This is the agent’s original workbook. Its review didn’t finish, so it hasn’t been checked or repaired.

Open in Shortcut ↗Download XLSX ↓

Shortcut’s reasoning.

Basis: consensus normalized actuals equal Tempus non-GAAP net loss per basic share every quarter (e.g., 2Q26 -$0.04); the frozen -$0.08 mean (high $0.00) looks mixed with analysts who leave in ~$16.6m/qtr acquired-intangible amortization (~$0.09/share) and stale interest.

Refinancing: the May-2026 $460m 0% 2032 converts repaid the ~12.5% Ares term loan and revolver; 3Q26 interest expense built by instrument is ~$6.8m vs $10.3m in 2Q26 and $12.2m consensus.

Operations: revenue $410.4m (consensus $409.3m) from oncology 103k tests (MRD 12.5k), hereditary 147.5k tests, Insights $89m (+29% Y/Y after ~$200m 2Q bookings); fits FY26 guide $1.595-1.605bn.

Adj. EBITDA $20.6m sits on the path to FY26 ~$65m (1H26 $5.2m); non-GAAP NI = Adj. EBITDA - D&A ex-acquired amortization + net interest = $7.9m, or +$0.044/share.

Downside check: holding other lines, reported EPS fails to strictly beat -$0.08 only if Adj. EBITDA falls below about -$1m (vs 2Q26 +$8.0m and guidance for positive quarters); the 4Q25 Adj. EBITDA miss vs its ~$20m guide and basis risk keep confidence at medium.

Prior: large cap ($13.0bn), 6/6 strict beats, so starting p = (8x0.78+6)/14 = 0.874. Raised to 0.92 on the model gap; no EPS bump applied.

On the record.

Reporting period: FQ3 2026 (quarter ended 2026-09-30)
Reporting basis: Normalized: company non-GAAP net income (loss) per basic weighted Class A+B common share, USD (the basis of consensus normalized actuals in all six history quarters)
Consensus snapshot: November 1, 2026
Model / effort: Opus 5.5 · High effort
Workbook: Original workbook · review incomplete

Record history

Forecast generated: Nov 1, 2026 at 9:18 PM PST
First posted: Nov 2, 2026 at 3:21 PM PST
Result checked: Nov 2, 2026 at 5:14 PM PST

Result basis

Provider 0.07 agrees with issuer nonGAAP per-share figure 0.07, distinct from GAAP loss 0.08. No substitution of EBITDA.